quinazolines has been researched along with Multiple Sclerosis in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| André, MC; Antunes, J; Filipe, P; Pacheco, D; Silva, R; Soares de Almeida, LM | 1 |
| Furberg, CD; Moore, TJ | 1 |
| Deng, X; Sriram, S | 1 |
| Aul, C; Schroeder, M | 1 |
1 review(s) available for quinazolines and Multiple Sclerosis
| Article | Year |
|---|---|
Role of microglia in multiple sclerosis.
Topics: Animals; Disease Models, Animal; Encephalomyelitis, Acute Disseminated; Encephalomyelitis, Autoimmune, Experimental; Humans; Microglia; Models, Biological; Multiple Sclerosis; Quinazolines; T-Lymphocytes | 2005 |
3 other study(ies) available for quinazolines and Multiple Sclerosis
| Article | Year |
|---|---|
Generalized skin drug eruption to natalizumab in a patient with multiple sclerosis.
Topics: Adult; Amitriptyline; Antibodies; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzodiazepines; Carbamazepine; Clorazepate Dipotassium; Drug Eruptions; Eosinophilia; Glatiramer Acetate; Humans; Interferon beta-1a; Interferon-beta; Liver; Male; Multiple Sclerosis; Natalizumab; Peptides; Quinazolines; Thrombocytopenia | 2010 |
The safety risks of innovation: the FDA's Expedited Drug Development Pathway.
Topics: Anticoagulants; Antineoplastic Agents; Benzimidazoles; beta-Alanine; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Dabigatran; Drug Approval; Efficiency, Organizational; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Patient Safety; Piperidines; Propylene Glycols; Quinazolines; Risk; Sphingosine; Stroke; Thyroid Neoplasms; Time Factors; United States; United States Food and Drug Administration | 2012 |
[Anti-angiogenic therapy of a renal angiomyolipoma in a seriously disabled patient suffering from multiple sclerosis].
Topics: Administration, Oral; Angiogenesis Inhibitors; Angiomyolipoma; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Kidney Neoplasms; Middle Aged; Multiple Sclerosis; Neoplasms, Second Primary; Nephrectomy; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2005 |